Rosetta Genomics to Host Business Update and 2015 Year-End Financial Results Conference Call on March 23, 2016
March 17 2016 - 8:30AM
Business Wire
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics, today
announced that following the close of the U.S. stock market on
Wednesday, March 23, 2016, the Company will file its financial
results for the 12 months ended December 31, 2015 on Form 20-F with
the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F
will include audited consolidated financial statements, as well as
additional information regarding the Company. The Form 20-F will be
available at www.sec.gov and at www.rosettagenomics.com.
Kenneth A. Berlin, President and Chief Executive Officer of
Rosetta Genomics, and Ron Kalfus, Chief Financial Officer of
Rosetta Genomics, will host a conference call on Wednesday, March
23, 2016 at 5:00 p.m. Eastern time to provide an update on the
Company’s business and respond to questions.
Individuals interested in listening to the conference call may
do so by dialing (866) 239-5859, or for international callers (702)
495-1913. The conference ID number is 72929451. The call is also
being webcast, and can be accessed on the investor relations
section of the Company’s website at www.rosettagx.com.
A telephone replay will be available through March 29, 2016 by
dialing (855) 859-2056 or for international callers (404) 537-3406,
and entering the Conference ID number 72929451. The webcast will be
available on the Company’s website for 30 days following the
completion of the call.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based and other molecular diagnostics. Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Through the acquisition
of PersonalizeDx, the Company now offers core FISH, IHC and
PCR-based testing capabilities and partnerships in Pathology,
Oncology and Urology that provide additional content and platforms
that complement Rosetta’s microRNA and Next-Gen Sequencing
offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the
diagnosis of indeterminate thyroid FNA smears, as well as the full
RosettaGX™ portfolio of cancer testing services are commercially
available through the Company’s Philadelphia, PA- and Lake Forest,
CA-based CAP-accredited, CLIA-certified labs, respectively. For
more information visit www.rosettagx.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects constitute forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including
those risks more fully discussed in the "Risk Factors" section of
Rosetta’s Annual Report on Form 20-F for the year ended December
31, 2014 as filed with the SEC. In addition, any
forward-looking statements represent Rosetta’s views only as of the
date of this release and should not be relied upon as representing
its views as of any subsequent date. Rosetta does not assume any
obligation to update any forward-looking statements unless required
by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160317005469/en/
Rosetta GenomicsKen Berlin, President & CEO(267)
298-1159investors@rosettagenomics.comorRosetta Genomics
InvestorLHAAnne Marie Fields(212) 838-3777afields@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024